P176 Ixekizumab significantly improves nail disease and adjacent joint tenderness and swelling in psoriatic arthritis
McGonagle D, Kavanaugh A, McInnes I, Kristensen L, Merola J, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C. P176 Ixekizumab significantly improves nail disease and adjacent joint tenderness and swelling in psoriatic arthritis. Rheumatology 2024, 63: keae163.215. DOI: 10.1093/rheumatology/keae163.215.Peer-Reviewed Original ResearchPost-baseline assessmentTreatment effectsEli Lilly and CompanyPost hoc analysisSevere functional impairmentStudy of adultsNail PsOFunctional impairmentAdjacent joint diseaseSPIRIT-H2HGroup levelHoc analysisPsoriatic arthritisJoint tendernessNail diseaseIndividual digitsPatients treated with ixekizumabNon-respondersEli LillyUCB PharmaJoint involvementJoint swellingCorEvitas Psoriasis RegistryCount scoreTreated with adalimumabAssociation of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis
McGonagle D, Kavanaugh A, McInnes I, Kristensen L, Merola J, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis. Rheumatology 2024, 63: 3115-3123. PMID: 38341669, PMCID: PMC11534097, DOI: 10.1093/rheumatology/keae060.Peer-Reviewed Original ResearchNail psoriasisJoint involvementPsoriatic arthritisJoint tendernessTargeting IL-17ADistal interphalangeal joint involvementPost hoc analysisPost-baseline assessmentSPIRIT-H2HInhibitor adalimumabIL-17AAdalimumabStudy cohortTNF-aDrug classesMusculoskeletal outcomesPsoriasisPatientsHoc analysisDistal interphalangealIxekizumabSynovio-entheseal complexWeeksAdjacent nailPSA